DCK and plasma cell myeloma: Other miR-155 targets associated with chemoresistance include the gemcitabine-metabolizing enzyme deoxycytidine kinase (DCK) in pancreatic cancer [18] and tumor necrosis factor-α-inducible protein 8 (TNFAIP8) in bortezomib-resistant multiple myeloma cells [24].